A randomized clinical trial on sentinel lymph node biopsy versus axillary lymph node dissection in breast cancer: Results of the sentinella/GIVOM trial

Giorgio Zavagno, Gian Luca De Salvo, Giuliano Scalco, Fernando Bozza, Luca Barutta, Paola Del Bianco, Marco Renier, Carlo Racano, Paolo Carraro, Donato Nitti

Research output: Contribution to journalArticle

228 Citations (Scopus)

Abstract

OBJECTIVE: The aim of this multicenter randomized trial was to assess the efficacy and safety of sentinel lymph node (SLN) biopsy compared with axillary lymph node dissection (ALND). BACKGROUND: All studies on SLN biopsy in breast cancer report a variable false negative rate, whose prognostic consequences are still unclear. METHODS: From May 1999 to December 2004, patients with breast cancer ≤3 cm were randomly assigned to receive SLN biopsy associated with ALND (ALND arm) or SLN biopsy followed by ALND only if the SLN was metastatic (SLN arm). The main aim was the comparison of disease-free survival in the 2 arms. RESULTS: A total of 749 patients were randomized and 697 were available for analysis. SLNs were identified in 662 of 697 patients (95%) and positive SLNs were found in 189 of 662 patients (28.5%). In the ALND group, positive non-SLNs were found in 18 patients with negative SLN, giving a false negative rate of 16.7% (18 of 108). Postoperative side effects were significantly less in the SLN group and there was no negative impact of the SLN procedure on psychologic well being. At a median follow-up of 56 months, there were more locoregional recurrences in the SLN arm, and the 5-year disease-free survival was 89.9% in the ALND arm and 87.6% in the SLN arm, with a difference of 2.3% (95% confidence interval: -3.1% to 7.6%). However, the number of enrolled patients was not sufficient to draw definitive conclusions. CONCLUSION: SLN biopsy is an effective and well-tolerated procedure. However, its safety should be confirmed by the results of larger randomized trials and meta-analyses.

Original languageEnglish
Pages (from-to)207-213
Number of pages7
JournalAnnals of Surgery
Volume247
Issue number2
DOIs
Publication statusPublished - Feb 2008

Fingerprint

Sentinel Lymph Node Biopsy
Lymph Node Excision
Randomized Controlled Trials
Breast Neoplasms
Disease-Free Survival
Safety
Sentinel Lymph Node
Multicenter Studies
Meta-Analysis
Confidence Intervals
Recurrence

ASJC Scopus subject areas

  • Surgery

Cite this

A randomized clinical trial on sentinel lymph node biopsy versus axillary lymph node dissection in breast cancer : Results of the sentinella/GIVOM trial. / Zavagno, Giorgio; De Salvo, Gian Luca; Scalco, Giuliano; Bozza, Fernando; Barutta, Luca; Del Bianco, Paola; Renier, Marco; Racano, Carlo; Carraro, Paolo; Nitti, Donato.

In: Annals of Surgery, Vol. 247, No. 2, 02.2008, p. 207-213.

Research output: Contribution to journalArticle

Zavagno, Giorgio ; De Salvo, Gian Luca ; Scalco, Giuliano ; Bozza, Fernando ; Barutta, Luca ; Del Bianco, Paola ; Renier, Marco ; Racano, Carlo ; Carraro, Paolo ; Nitti, Donato. / A randomized clinical trial on sentinel lymph node biopsy versus axillary lymph node dissection in breast cancer : Results of the sentinella/GIVOM trial. In: Annals of Surgery. 2008 ; Vol. 247, No. 2. pp. 207-213.
@article{595661274c5045a99b3a3e4bb8513c22,
title = "A randomized clinical trial on sentinel lymph node biopsy versus axillary lymph node dissection in breast cancer: Results of the sentinella/GIVOM trial",
abstract = "OBJECTIVE: The aim of this multicenter randomized trial was to assess the efficacy and safety of sentinel lymph node (SLN) biopsy compared with axillary lymph node dissection (ALND). BACKGROUND: All studies on SLN biopsy in breast cancer report a variable false negative rate, whose prognostic consequences are still unclear. METHODS: From May 1999 to December 2004, patients with breast cancer ≤3 cm were randomly assigned to receive SLN biopsy associated with ALND (ALND arm) or SLN biopsy followed by ALND only if the SLN was metastatic (SLN arm). The main aim was the comparison of disease-free survival in the 2 arms. RESULTS: A total of 749 patients were randomized and 697 were available for analysis. SLNs were identified in 662 of 697 patients (95{\%}) and positive SLNs were found in 189 of 662 patients (28.5{\%}). In the ALND group, positive non-SLNs were found in 18 patients with negative SLN, giving a false negative rate of 16.7{\%} (18 of 108). Postoperative side effects were significantly less in the SLN group and there was no negative impact of the SLN procedure on psychologic well being. At a median follow-up of 56 months, there were more locoregional recurrences in the SLN arm, and the 5-year disease-free survival was 89.9{\%} in the ALND arm and 87.6{\%} in the SLN arm, with a difference of 2.3{\%} (95{\%} confidence interval: -3.1{\%} to 7.6{\%}). However, the number of enrolled patients was not sufficient to draw definitive conclusions. CONCLUSION: SLN biopsy is an effective and well-tolerated procedure. However, its safety should be confirmed by the results of larger randomized trials and meta-analyses.",
author = "Giorgio Zavagno and {De Salvo}, {Gian Luca} and Giuliano Scalco and Fernando Bozza and Luca Barutta and {Del Bianco}, Paola and Marco Renier and Carlo Racano and Paolo Carraro and Donato Nitti",
year = "2008",
month = "2",
doi = "10.1097/SLA.0b013e31812e6a73",
language = "English",
volume = "247",
pages = "207--213",
journal = "Annals of Surgery",
issn = "0003-4932",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - A randomized clinical trial on sentinel lymph node biopsy versus axillary lymph node dissection in breast cancer

T2 - Results of the sentinella/GIVOM trial

AU - Zavagno, Giorgio

AU - De Salvo, Gian Luca

AU - Scalco, Giuliano

AU - Bozza, Fernando

AU - Barutta, Luca

AU - Del Bianco, Paola

AU - Renier, Marco

AU - Racano, Carlo

AU - Carraro, Paolo

AU - Nitti, Donato

PY - 2008/2

Y1 - 2008/2

N2 - OBJECTIVE: The aim of this multicenter randomized trial was to assess the efficacy and safety of sentinel lymph node (SLN) biopsy compared with axillary lymph node dissection (ALND). BACKGROUND: All studies on SLN biopsy in breast cancer report a variable false negative rate, whose prognostic consequences are still unclear. METHODS: From May 1999 to December 2004, patients with breast cancer ≤3 cm were randomly assigned to receive SLN biopsy associated with ALND (ALND arm) or SLN biopsy followed by ALND only if the SLN was metastatic (SLN arm). The main aim was the comparison of disease-free survival in the 2 arms. RESULTS: A total of 749 patients were randomized and 697 were available for analysis. SLNs were identified in 662 of 697 patients (95%) and positive SLNs were found in 189 of 662 patients (28.5%). In the ALND group, positive non-SLNs were found in 18 patients with negative SLN, giving a false negative rate of 16.7% (18 of 108). Postoperative side effects were significantly less in the SLN group and there was no negative impact of the SLN procedure on psychologic well being. At a median follow-up of 56 months, there were more locoregional recurrences in the SLN arm, and the 5-year disease-free survival was 89.9% in the ALND arm and 87.6% in the SLN arm, with a difference of 2.3% (95% confidence interval: -3.1% to 7.6%). However, the number of enrolled patients was not sufficient to draw definitive conclusions. CONCLUSION: SLN biopsy is an effective and well-tolerated procedure. However, its safety should be confirmed by the results of larger randomized trials and meta-analyses.

AB - OBJECTIVE: The aim of this multicenter randomized trial was to assess the efficacy and safety of sentinel lymph node (SLN) biopsy compared with axillary lymph node dissection (ALND). BACKGROUND: All studies on SLN biopsy in breast cancer report a variable false negative rate, whose prognostic consequences are still unclear. METHODS: From May 1999 to December 2004, patients with breast cancer ≤3 cm were randomly assigned to receive SLN biopsy associated with ALND (ALND arm) or SLN biopsy followed by ALND only if the SLN was metastatic (SLN arm). The main aim was the comparison of disease-free survival in the 2 arms. RESULTS: A total of 749 patients were randomized and 697 were available for analysis. SLNs were identified in 662 of 697 patients (95%) and positive SLNs were found in 189 of 662 patients (28.5%). In the ALND group, positive non-SLNs were found in 18 patients with negative SLN, giving a false negative rate of 16.7% (18 of 108). Postoperative side effects were significantly less in the SLN group and there was no negative impact of the SLN procedure on psychologic well being. At a median follow-up of 56 months, there were more locoregional recurrences in the SLN arm, and the 5-year disease-free survival was 89.9% in the ALND arm and 87.6% in the SLN arm, with a difference of 2.3% (95% confidence interval: -3.1% to 7.6%). However, the number of enrolled patients was not sufficient to draw definitive conclusions. CONCLUSION: SLN biopsy is an effective and well-tolerated procedure. However, its safety should be confirmed by the results of larger randomized trials and meta-analyses.

UR - http://www.scopus.com/inward/record.url?scp=38549157503&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38549157503&partnerID=8YFLogxK

U2 - 10.1097/SLA.0b013e31812e6a73

DO - 10.1097/SLA.0b013e31812e6a73

M3 - Article

C2 - 18216523

AN - SCOPUS:38549157503

VL - 247

SP - 207

EP - 213

JO - Annals of Surgery

JF - Annals of Surgery

SN - 0003-4932

IS - 2

ER -